Protozoan Parasite Increases Risk of Colitis, Study Reveals

In recent years, researchers have discovered that the trillions of bacteria that reside in the gastrointestinal tract have an enormous impact on human health and disease. But the effects of other types of microorganisms that live in the gut, such as the unicellular eukaryotes known as protozoans, are less well understood. Though some protozoan species, which are part of the protist kingdom of life, cause diseases like malaria and leishmaniasis, the protozoa that commonly live in the gut are generally thought to be harmless.

While studying the inflammatory mechanisms underlying colitis in rodents, a team of researchers led by Dana Philpott and Thierry Mallevaey realized that their laboratory mice were more susceptible to developing the disease if their intestines were already infected with the protozoan Tritrichomonas muris. This parasite is commonly found in the intestines of mice, and the researchers observed that its presence raised the levels of pro-inflammatory T cells and cytokines in the host animal’s gut. These inflammatory factors may “prime” the intestinal tissue to become inflamed, leaving it more susceptible to colitis.

A recent study published in Cell revealed that, while the related parasite Tritrichomonas musculis makes the intestine susceptible to both colitis and colorectal cancer, it induces an immune response that protects mice against Salmonella infection. This may be why host animals tolerate protozoans such as T. muris living in their intestines. Several species of protozoa reside in the human gut, and some of them are prevalent in patients with gastrointestinal disease, suggesting that similar host–parasite interactions could affect human health. “Our findings highlight the need for a better understanding of cross-kingdom interactions between host and protozoa within the gastrointestinal tract,” says Philpott.

Escalante, N.K., et al. 2016. J. Exp. Med. http://dx.doi.org/10.1084/jem.20161776

# # #

About The Journal of Experimental MedicineThe Journal of Experimental Medicine (JEM) features peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions are made by research-active scientists in conjunction with in-house scientific editors. JEM provides free online access to many article types from the date of publication and to all archival content. Established in 1896, JEM is published by The Rockefeller University Press. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.